3
Participants
Start Date
January 11, 2017
Primary Completion Date
April 22, 2019
Study Completion Date
April 22, 2019
IMCgp100
Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
Memorial Slone Kettering Cancer Center, New York
Dept of Oncology & Haematology, Churchill Hospital, Oxford
Dept of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow
Lead Sponsor
Immunocore Ltd
INDUSTRY